SQZ Biotechnologies PE Ratio 2020-2022 | SQZ

Current and historical p/e ratio for SQZ Biotechnologies (SQZ) from 2020 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. SQZ Biotechnologies PE ratio as of January 26, 2023 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

SQZ Biotechnologies PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2023-01-26 0.84 0.00
2022-09-30 2.28 $-2.71 0.00
2022-06-30 3.18 $-2.74 0.00
2022-03-31 4.81 $-2.64 0.00
2021-12-31 8.93 $-2.48 0.00
2021-09-30 14.42 $-2.07 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.024B $0.027B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.571B 9.49
GSK (GSK) United Kingdom $71.996B 8.97
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.433B 19.52
Ginkgo Bioworks Holdings (DNA) United States $3.414B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.676B 25.16
Biohaven (BHVN) United States $1.305B 0.00
Emergent Biosolutions (EBS) United States $0.671B 5.28
ADC Therapeutics SA (ADCT) Switzerland $0.359B 0.00
Ambrx Biopharma (AMAM) United States $0.083B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.028B 0.00